Susquehanna International Group, LLP Point Biopharma Global Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.67 - $9.71 $46,943 - $68,338	-7,038 Reduced 21.19%	26,183 $174,000
Q2 2023 Aug 11, 2023	SELL	$6.86 - $10.86 $541,631 - $857,451	-78,955 Reduced 70.38%	33,221 $300,000
Q1 2023 May 16, 2023	BUY	$6.78 - $8.1 $588,395 - $702,950	86,784 Added 341.78%	112,176 $815,000
Q4 2022 Feb 14, 2023	SELL	$5.72 - $9.78 $221,587 - $378,867	-38,739 Reduced 60.41%	25,392 $185,000
Q3 2022 Nov 14, 2022	SELL	$7.24 - $10.31 $236,125 - $336,250	-32,614 Reduced 33.71%	64,131 $496,000
Q2 2022 Aug 15, 2022	SELL	$5.6 - $9.5 $1.89 Million - $3.2 Million	-337,256 Reduced 77.71%	96,745 $659,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.13 $2.37 Million - $3.53 Million	434,001 New	434,001 $3.46 Million

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.